Matches in Wikidata for { <http://www.wikidata.org/entity/Q64238252> ?p ?o ?g. }
- Q64238252 description "im Mai 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q64238252 description "wetenschappelijk artikel" @default.
- Q64238252 description "наукова стаття, опублікована в травні 2019" @default.
- Q64238252 name "Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTO" @default.
- Q64238252 name "Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTO" @default.
- Q64238252 type Item @default.
- Q64238252 label "Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTO" @default.
- Q64238252 label "Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTO" @default.
- Q64238252 prefLabel "Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTO" @default.
- Q64238252 prefLabel "Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTO" @default.
- Q64238252 P1433 Q64238252-C0BE761B-65A9-4EA2-968C-4C1449F82205 @default.
- Q64238252 P1476 Q64238252-A3E65B67-E838-4108-9C1C-5ADC783931E0 @default.
- Q64238252 P2093 Q64238252-041DA009-AAFE-442E-88AD-27017E3EAA08 @default.
- Q64238252 P2093 Q64238252-054FFAC2-83C4-4AF0-A5BF-B7C2ADCD8915 @default.
- Q64238252 P2093 Q64238252-17F59CEB-E125-4A34-868B-75182EF7399E @default.
- Q64238252 P2093 Q64238252-18437ABC-2397-4E0F-9779-692C1404CBEA @default.
- Q64238252 P2093 Q64238252-6CEEFB07-6E7C-4618-A51E-F78CA7764DB2 @default.
- Q64238252 P2093 Q64238252-BEF9F2E1-93AB-4573-AD7C-2790F70C23F7 @default.
- Q64238252 P2093 Q64238252-E59BFB85-057C-45DC-A476-0ACC938D3E0B @default.
- Q64238252 P2093 Q64238252-F3B0797F-21EB-4C01-B2CD-41FC028DA99A @default.
- Q64238252 P2093 Q64238252-FB4AE689-9509-469D-9994-60CDDFCBB70D @default.
- Q64238252 P2093 Q64238252-FE836146-75D6-4AC6-B68A-A48D924BDB3D @default.
- Q64238252 P2860 Q64238252-02782A81-2416-4345-A51C-7538A94115E9 @default.
- Q64238252 P2860 Q64238252-044A2B90-2E8D-49BD-B110-62A1A642181B @default.
- Q64238252 P2860 Q64238252-05BC8E1E-EAA4-4C0C-805F-C2AA4CA38F08 @default.
- Q64238252 P2860 Q64238252-094934A3-164E-488D-A3DA-F1F768A58FC8 @default.
- Q64238252 P2860 Q64238252-20230ECA-4415-4CA9-BBC1-6B9813A7E4F2 @default.
- Q64238252 P2860 Q64238252-21F105EA-0C9B-4F2D-9F4C-89866A87765D @default.
- Q64238252 P2860 Q64238252-27BB5CC8-5149-4B8B-9427-17E391F419B7 @default.
- Q64238252 P2860 Q64238252-369CA0FD-FD1A-4FE5-BE29-B21983E2ACB5 @default.
- Q64238252 P2860 Q64238252-48401AA5-4318-49D2-956E-C6AA7D428E1C @default.
- Q64238252 P2860 Q64238252-574D1318-D2EA-4F97-BD58-C0770493D6C8 @default.
- Q64238252 P2860 Q64238252-6613752C-E477-479D-9372-DC67F8C99ADF @default.
- Q64238252 P2860 Q64238252-66FD738B-BE12-432C-BE9C-F471046E71F8 @default.
- Q64238252 P2860 Q64238252-6E91DFC5-0E99-4B78-B80A-07ECD146AF31 @default.
- Q64238252 P2860 Q64238252-727F2941-9CB7-4007-9BE0-7FF83A9985EB @default.
- Q64238252 P2860 Q64238252-77F6E677-A2FC-4894-A550-E5AC95D3C354 @default.
- Q64238252 P2860 Q64238252-7D8DBFAF-A67C-4F0C-BC50-128FBB44A179 @default.
- Q64238252 P2860 Q64238252-8AA26918-EB4B-4628-9338-EDDD0A55203D @default.
- Q64238252 P2860 Q64238252-8C4A58F1-BBF8-4E51-9E4A-537B5AFC99AB @default.
- Q64238252 P2860 Q64238252-8F2468A1-924F-40F5-A8EB-5BC59B56D36C @default.
- Q64238252 P2860 Q64238252-942F248D-9FA6-4928-8D96-4779D56A2C7E @default.
- Q64238252 P2860 Q64238252-94E5BFE3-66AC-4233-A303-31269C27ADEF @default.
- Q64238252 P2860 Q64238252-991F721A-5812-4D3C-B836-F076869DF1D7 @default.
- Q64238252 P2860 Q64238252-A4AE6CC3-E04D-4E0F-A760-08EC852CA5B1 @default.
- Q64238252 P2860 Q64238252-B1CFAD11-D505-4820-BDD5-59CEB2960EC4 @default.
- Q64238252 P2860 Q64238252-C757EAB3-F5DC-4E7B-B30A-A9BA3FCFDA4C @default.
- Q64238252 P2860 Q64238252-D310D130-E64D-4CB2-A1A4-18F6EF5034FE @default.
- Q64238252 P2860 Q64238252-E16CF907-6075-41B8-9673-636622E464CF @default.
- Q64238252 P2860 Q64238252-E7E9AFCF-C740-494B-A40D-2D1078BE0417 @default.
- Q64238252 P2860 Q64238252-F2556ADE-D1FB-470E-9C1B-328D362903E6 @default.
- Q64238252 P304 Q64238252-A39C6B17-6D19-4D75-ACDC-140689CD0705 @default.
- Q64238252 P31 Q64238252-B54E3F25-D981-416A-B4EE-A23B496AAFC5 @default.
- Q64238252 P356 Q64238252-6E5EB11D-9C44-45D1-AFC0-022139F2290B @default.
- Q64238252 P407 Q64238252-6536FC93-2B61-4AB4-95C0-47B4C40B08D2 @default.
- Q64238252 P433 Q64238252-6C3D75CC-337D-4B7D-984F-AA8F8708BAB7 @default.
- Q64238252 P478 Q64238252-3BD4FF49-8707-4877-BC44-FF6168C815B2 @default.
- Q64238252 P577 Q64238252-4382B0AD-5968-4B79-84E1-CE738C199758 @default.
- Q64238252 P698 Q64238252-C5EE322E-8351-436F-A0B9-A5000FB0F431 @default.
- Q64238252 P921 Q64238252-160DB322-986D-4A55-8076-8BBA1608D84D @default.
- Q64238252 P921 Q64238252-37D05BDF-A769-4469-B87A-FCC0B06D13CB @default.
- Q64238252 P932 Q64238252-AA9C8CA9-E652-4ADE-BF31-0988B066EFF9 @default.
- Q64238252 P356 COC.0000000000000538 @default.
- Q64238252 P698 30950859 @default.
- Q64238252 P1433 Q2886177 @default.
- Q64238252 P1476 "Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTO" @default.
- Q64238252 P2093 "Hong-Bing Liu" @default.
- Q64238252 P2093 "Jian-Hua Chen" @default.
- Q64238252 P2093 "Jie Wang" @default.
- Q64238252 P2093 "Jing-Yan Ding" @default.
- Q64238252 P2093 "Jiu-Wei Cui" @default.
- Q64238252 P2093 "Le-Jie Cao" @default.
- Q64238252 P2093 "Min Hu" @default.
- Q64238252 P2093 "Yi-Long Wu" @default.
- Q64238252 P2093 "Yong Song" @default.
- Q64238252 P2093 "Zhi-Yong Ma" @default.
- Q64238252 P2860 Q24794765 @default.
- Q64238252 P2860 Q27824829 @default.
- Q64238252 P2860 Q27851633 @default.
- Q64238252 P2860 Q27860881 @default.
- Q64238252 P2860 Q27861047 @default.
- Q64238252 P2860 Q28131668 @default.
- Q64238252 P2860 Q29547545 @default.
- Q64238252 P2860 Q29614275 @default.
- Q64238252 P2860 Q29619975 @default.
- Q64238252 P2860 Q34159240 @default.
- Q64238252 P2860 Q34361336 @default.
- Q64238252 P2860 Q34974381 @default.
- Q64238252 P2860 Q35196345 @default.
- Q64238252 P2860 Q36574146 @default.
- Q64238252 P2860 Q37130325 @default.
- Q64238252 P2860 Q38673986 @default.
- Q64238252 P2860 Q40263469 @default.
- Q64238252 P2860 Q42362771 @default.
- Q64238252 P2860 Q42743610 @default.
- Q64238252 P2860 Q42780600 @default.
- Q64238252 P2860 Q43297381 @default.
- Q64238252 P2860 Q46452681 @default.
- Q64238252 P2860 Q47667903 @default.
- Q64238252 P2860 Q51360283 @default.